Navigation Links
CDC Issues New TB Treatment Guidelines
Date:12/8/2011

THURSDAY, Dec. 8 (HealthDay News) -- New guidelines on treating so-called "latent" tuberculosis infection in the United States should significantly shorten and simplify the course of the therapy from about 9 months to 3 months, according to the U.S. Centers for Disease Control and Prevention.

The new guidelines for public health officials and health care providers -- which are based on expert opinion and the results of three clinical trials -- are a "game changer" for the treatment of TB in the United States, according to CDC Director Dr. Thomas Frieden.

Latent TB infection occurs when a person is infected with TB bacteria but does not yet have symptoms and so cannot transmit the bacteria to others. However, if the bacteria becomes active, the person will develop the disease and can also spread it to others.

Certain people, including those with weakened immune systems, are more likely to progress from latent to active TB. The CDC notes, however, that many high-risk people with latent TB feel fine and don't begin the nine-month course of treatment, which typically requires 270 daily doses of the anti-TB drug isoniazid. And many of those who do begin the therapy don't see it through to the end.

However, the new regimen streamlines the treatment to 12 once-per-week doses of isoniazid, along with another anti-TB drug called rifapentine.

"This regimen has the potential to be a game-changer in the United States when it comes to fighting TB," Frieden said in a CDC news release. "It gives us a new, effective option that will reduce by two-thirds -- from nine months to three months -- the length of time someone needs to take medicine to prevent latent TB infection from progressing to active TB disease."

The new guidelines were published in the Dec. 9 issue of the CDC's Morbidity and Mortality Weekly Report.

"If we are going to achieve our goal of TB elimination in the United States, we must ensure that those with latent TB infection receive appropriate evaluation and treatment to prevent their infection from progressing to TB disease and possibly spreading to others," Dr. Kevin Fenton, director of CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, said in the news release.

"It is critical that we accelerate progress against TB in the United States in order to avoid a resurgence of the disease," he added.

The number of people in the United States with TB remains at an all-time low, with just over 11,000 cases reported in 2010. However, about 4 percent of the U.S. population (11 million people) are infected with the TB bacterium. The CDC also noted that foreign-born people and people of color in the United States are disproportionately affected by the illness.

These new guidelines apply only to the United States, CDC officials said. Further research is likely needed before this regimen could be recommended for countries with a high incidence of TB, particularly those that have high rates of HIV and where there's a greater risk of TB re-infection.

More information

The American Lung Association has more about TB.

-- Robert Preidt

SOURCE: U.S. Centers for Disease Control and Prevention, news release, Dec. 8, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. American Society of Clinical Oncology issues annual report on progress against cancer
2. AAOS issues new clinical practice guideline for treating common elbow fractures in children
3. Experts Design Toolkit to Help Spot Teens With Mental Health Issues
4. Programming cells to home to specific tissues may enable more effective cell-based therapies
5. Study highlights issues faced by friends and family of the suicidal
6. People With Mental Health Issues More Likely to Be Uninsured
7. Rebooting the system: Immune cells repair damaged lung tissues after flu infection
8. Academic issues warning on schoolboy rugby
9. CDC Issues Guidance for Coping With Lingering Heat
10. ADHD, Learning Issues May Be Linked to Secondhand Smoke
11. Emotional, Behavioral Issues Affect Many Kids in Foster Care
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CDC Issues New TB Treatment Guidelines
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Prater Eye Center becomes the first in the area to offer AngioPlex™ Optical ... signs of retinal disease, such as macular degeneration, diabetic retinopathy, and other vascular ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... Many individuals ... of protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved ... it once more, but without the high-carb repercussions. IsoPasta has 30 grams of ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, ... gift of a VeinViewer® Vision vein finder for the nursing school ... an IV and draw blood, combining technology with traditional technique. , “VeinViewer is ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... According ... hernia surgeries are beginning to account for a significant portion of hernia repairs throughout ... Towfigh of the Beverly Hills Hernia Center notes that this trend has not only ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted over 250 members of South Florida’s philanthropic community at its 10th ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)...  Sequent Medical, Inc. announced today that it has ... safety and effectiveness of the WEB™ Aneurysm Embolization System ... Prof Laurent Spelle , MD, Head of Neuroradiology ... and Principal Investigator of the CLARYS study, ... and Germany.  Although patients with ruptured aneurysms have ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... WILMINGTON, North Carolina , 12 februari ... Laboratories, Inc. (AAI/CML), een toonaangevende leverancier van ... farmaceutische en biotechnologische industrieën, kondigt vandaag een ... en mogelijkheden op haar locatie in ... in vraag heeft geleid tot meerdere recente ...
Breaking Medicine Technology: